Recce topical gel shows strong diabetic foot infection efficacy ahead of Phase III data review Posted on October 20, 2026 by recce_com Recce topical gel shows strong diabetic foot infection efficacy ahead of Phase III data review
Building a Commercial Path for a New Antibacterial Platform Posted on October 13, 2026October 20, 2026 by recce_com Building a Commercial Path for a New Antibacterial Platform
Recce approval has R327G go head-to-head with antibiotic treatments Posted on August 19, 2026 by recce_com Recce approval has R327G go head-to-head with antibiotic treatments
Recce advances anti-infective gel to Phase III trial for diabetic foot infections in Australia Posted on June 22, 2026 by recce_com Recce advances anti-infective gel to Phase III trial for diabetic foot infections in Australia
New diabetic foot infection treatment could reach Morocco under regional deal Posted on May 29, 2026 by recce_com New diabetic foot infection treatment could reach Morocco under regional deal
Recce signs major MENA 10-year licensing deal Posted on May 28, 2026 by recce_com Recce signs major MENA 10-year licensing deal
ASX healthcare innovators target costly surgical complications and repeat procedures Posted on May 8, 2026May 8, 2026 by recce_com ASX healthcare innovators target costly surgical complications and repeat procedures
Recce clears regulatory inspection for Phase III DFI trial in Indonesia Posted on April 28, 2026 by recce_com Recce clears regulatory inspection for Phase III DFI trial in Indonesia
No more tears as Recce takes on antibiotic superbug crisis Posted on April 13, 2026 by recce_com No more tears as Recce takes on antibiotic superbug crisis
Inside Biotech: Recce Pharmaceuticals advances late-stage push in antibiotic resistance fight Posted on April 7, 2026 by recce_com Inside Biotech: Recce Pharmaceuticals advances late-stage push in antibiotic resistance fight
